~~<i id='DB2C079FDA'><strike id='DB2C079FDA'><tt id='DB2C079FDA'><pre id='DB2C079FDA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：Wikipedia 2025-09-30 16:27:54 - browse：11

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Letters to First Opinion on caregivers, digital health, and more

focus

leisure time

focus

knowledge

focus

ADAMFEUERSTEIN/STATCHICAGO—CorbusPharmaceuticalsisthesecondbest-performingbiotechstockthisyear,thank

WSS

How to increase colonoscopy rates? Looks like an AI can help

Cord blood banking comes at a high cost to babies

Letters to First Opinion on caregivers, digital health, and more

Mayo Clinic plans $5B tech

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

ReNAgade cuts staff seven months after raising $300 million

explore

Wikipedia

focus

23andMe had bad news about my health. I wish a person had delivered it

BMI, flaws aside, is found to be useful estimate of body fat in youth

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

See how much Covid

Wildfire smoke exposes gaps in outdoor worker protections

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Medical records are filled with copy

ASCO: AstraZeneca says CAR

Novavax promises a turnaround & Lilly roils the obesity market

FDA's Pazdur wants cancer trials to range beyond China alone

leisure time

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO: AstraZeneca says CAR

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

BMI, flaws aside, is found to be useful estimate of body fat in youth

With trial win, GSK could get blood cancer drug back on market

Disappointing trial forces Pfizer to pivot on obesity medicine plans

focus

knowledge

focus

focus